At last a silver lining for the dark clouds of skin cancer. Recent research, have reported that 9 out of 16 patients with the malignant skin cancer has experienced a significant shrinkage in their tumours. The research was conducted on the fact that the tumours were based on their genetic characteristics.
The experts are impressed with the outcomes, but the research was just conducted on a small scale. So the excitement of the positive results have triggered decisions and confirmations for the findings reflect the broader potential of genetic information to help researchers and clinicians select for treatment patients with higher chances of benefiting from a drug and steering those unlikely to respond to other options. The hope is that this approach will speed drug development and enable doctors to deliver care more cost-effectively.
The drug, known as a BRAF inhibitor, is being developed by Roche Holding AG, the Swiss pharmaceutical giant, and Plexxikon Inc., Berkeley, Calif. Large scale and more accurate studies. The study, sponsored by Plexxikon, was among scores of reports looking at the interaction of genetic biomarkers and cancer treatments presented at the annual meeting of the American
WINSLOW, RON. "Skin-Cancer Drug Uses Genetics - WSJ.com." Business News & Financial News - The Wall Street Journal - WSJ.com. http://online.wsj.com/article/SB124398850696479555.html (accessed June 1, 2009).
No comments:
Post a Comment